BLOG ARTICLE
Boston, November 24, 2021: Imran Haq, Pistoia Alliance’s Strategic Theme Lead for Emerging Science and Technology, gave us a preview of the exciting ideas to be discussed during this week’s webinar, “The Scientific Impact of Quantum Computing,” hosted by Robert Roe, editor of Scientific Computing World magazine.
The event was a perfect way to highlight his passion for the area where quantum computing intersects with the biopharmaceutical industry. For a recording of this webinar, go to www.scientific-computing.com.
Quantum computing expert Winfried Hensinger, of Universal Quantum, joined Haq on the panel. They both agreed that future applications are incredible, from commercial space travel to new, life-saving drugs.
“This tool is powerful,” Hensinger said. “It’s important for companies to engage with the technology early, otherwise, you’ll get left behind.”
Researchers have already started to use quantum computing to identify genetic patterns in Covid-19, for example, to predict which patients will have the most severe outcomes. While it may take more than a decade before all of these benefits come to fruition, Haq said, we need to start working together and collaborating right now.
So, if you want to know more, sign up for the Quantum Computing Community Summit on December 1. Seats are filling up fast, but it’s not too late to be part of this dynamic, innovative group. To register, click here to visit the event page on Hopin. Bring your most ambitious ideas and join us!
The Pistoia Alliance has over 150 members ranging from global research-led organizations and medium enterprises to start-ups and individuals. Members collaborate as equals on projects that generate concrete value for the worldwide life sciences and healthcare community. The Alliance provides members with a legal framework to enable straightforward and secure pre-competitive collaboration. Its full portfolio of projects is accessible here.
—ENDS—
About the Pistoia Alliance
The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology, and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 150 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using The Pistoia Alliance’s proven framework for open innovation.
Media Contact:
Spark Communications
+44 207 436 0420
pistoiaalliance@sparkcomms.co.uk
Tanya Randall
The Pistoia Alliance
+44 7887 811332
tanya.randall@pistoiaalliance.org